In 2013, the value of the Indian Pharmaceutical Market (IPM) grew 9.8% to INR 72069 crore ($12.3 billion), down from 16.6% in 2012. Slower growth has affected both leading Indian firms as well as multinational companies (MNCs), but growth has slowed more substantially for MNCs. The value of the five leading MNCs grew 16% in 2012, but only 7% in 2013. A total of 1,700 new products were introduced in 2012, compared to 1,900 in 2010. As of April 2013, the largest number of new products were anti-infectives (468), pain analgesics (435) and gastro-therapies (389). In 2013, the value of chronic therapies grew 14% to make up 30% of the IPM. The value of acute therapies grew 9.6% to represent 70%. The leading 10 firms were responsible for 41% of IPM value this year and grew 9% collectively.

Source: Confederation of Indian Industry and PwC